NeoTYPE® Profiles provide the widest spectrum of molecular profiles available, ranging from highly focused to broad genomic coverage for both solid tumor and hematologic malignancies.
NeoGenomics offers two unique levels of molecular profiling services that center on next-generation sequencing (NGS)-based testing to fit all of your cancer profiling needs. These two levels of services range from the more highly focused cancer-specific testing (28 cancer-specific profiles) to wide spectrum tumor testing (5 broad pan-tumor profiles). Together, these services provide you the flexibility you need in cancer testing and encompass all areas of molecular profiling to identify the hematologic and solid tumor diseases.
Advantages of the NeoTYPE® NGS Cancer Profiles include:
Breadth and focus: with three large pan-tumor Profiles and 28 targeted cancer-specific Profiles, NeoGenomics provides the widest variety of actionable tumor profiles suitable for every unique patient
Quantitative results: abnormal reports show percentage mutated gene vs. wild-type
Flexible level of service: FISH and most IHC components of NeoTYPE® Profiles may be ordered as Tech-Only or Global by pathology clients
Integrated reporting: comprehensive summary of results that includes diagnostic, prognostic, therapeutic and clinical trials information
Pharma ready: can be used in all phases of clinical trials and appropriate as a companion diagnostic
Highly focused molecular profiling with the NeoTYPE® Cancer-Specific Profiles delivers fast, actionable results
| AITL/Peripheral T-Cell Lymphoma | ALL | AML Prognostic | CLL Prognostic |
| Lymphoma | MDS/CMML | Follicular Lymphoma | |
| Brain | Breast | Cervical | Cholangiocarcinoma |
| Colorectal | Endometrial | Esophageal | Gastric |
| GI Predictive | GIST/Soft Tissue | Head & Neck | HRD+ Profile |
| Liposarcoma | Liver/Biliary | Lung | Melanoma |
| Other Solid Tumor | Ovarian | Pancreas | Thyroid |
NeoTYPE® Broad Reach Tumor Profiles for Heme & Solid Tumors
NCI-Match
The National Cancer Institute (NCI) and the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) co-developed the NCI Molecular Analysis for Therapy Choice (NCI-MATCH) study (also known as study EAY131). NCI-MATCH is a large precision medicine cancer trial with nearly 40 treatment arms exploring numerous genetic abnormalities and drugs in a large number of rare and common cancer types.
NeoGenomics is one of the designated laboratories in the NCI-MATCH trial and provides 19 different NeoTYPE® Solid Tumor Profiles that may qualify a patient for the study. Learn more
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients